Key terms

About MBRX

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MBRX news

Yesterday 9:07am ET Moleculin Biotech announces notification from USPTO regarding Annamycin Mar 25 3:12pm ET Moleculin Biotech Shares Corporate Update Presentation Mar 25 10:41am ET Moleculin Biotech trading resumes Mar 25 10:36am ET Moleculin Biotech trading halted, volatility trading pause Mar 25 7:42am ET Moleculin Biotech Announces Clinical Program Progress Updates Mar 25 7:32am ET Moleculin Biotech announces interim data on MB-106 Mar 21 7:50pm ET Moleculin Biotech trading halted, news pending Mar 20 7:42am ET Moleculin Biotech 2023 Financial Results Announcement and Webcast Mar 19 4:32pm ET Moleculin Biotech announces reverse stock split Feb 29 8:43am ET Moleculin Biotech Hosts Virtual Investor Strategy Call Feb 22 9:45am ET Moleculin Biotech’s Leadership Shares Company Insights Feb 15 9:32am ET Moleculin Biotech Virtual Update with CEO Walter Klemp Feb 14 4:54pm ET Moleculin Biotech Shares Corporate Update Online Feb 14 4:43pm ET Moleculin Biotech Stockholders Endorse Key Financial Proposals Feb 02 5:07pm ET Moleculin Biotech files to sell 14.09M shares of common stock for holders Jan 25 2:05pm ET Moleculin Biotech: A Strong Buy on Breakthrough Annamycin Trial Results Jan 25 4:13am ET Moleculin Biotech Unveils Annamycin Trial Progress and 2024 Outlook Jan 24 9:03am ET Moleculin Biotech reports expected upcoming milestones for 2024 Jan 24 8:58am ET Moleculin Biotech reports preliminary data on 2023-end annamycin clinical trials Dec 29 11:00am ET Biotech Alert: Searches spiking for these stocks today

No recent news articles are available for MBRX

No recent press releases are available for MBRX

MBRX Financials

1-year income & revenue

Key terms

MBRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MBRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms